|1.||Rothenberg, Marc E: 24 articles (10/2014 - 02/2002)|
|2.||Foster, Paul S: 23 articles (02/2015 - 02/2002)|
|3.||Takatsu, Kiyoshi: 20 articles (05/2015 - 03/2002)|
|4.||Bachert, Claus: 17 articles (05/2015 - 03/2004)|
|5.||O'Byrne, Paul M: 12 articles (04/2013 - 07/2002)|
|6.||McKenzie, Andrew N J: 12 articles (01/2013 - 06/2002)|
|7.||Lee, James J: 11 articles (02/2015 - 11/2004)|
|8.||Holtappels, Gabriele: 11 articles (01/2015 - 03/2004)|
|9.||Matthaei, Klaus I: 10 articles (02/2015 - 03/2002)|
|10.||Bachert, C: 10 articles (05/2012 - 09/2000)|
|1.||Asthma (Bronchial Asthma)
01/01/2001 - "TII is highly effective in treating asthma through regulating T-lymphocyte subset disorder and inhibiting production of IL-5."
07/01/2006 - "The absolute numbers of CD4+/CD25+ T lymphocyte and eosinophils, levels of ECP, and IL-5 were significantly greater, while forced expiratory volume in 1 second and peak expiratory flow rate were significantly less in the patients with asthma than in the control subjects on day 1. These parameters normalized after glucocorticoid treatment with clinical improvement by day 5. Glucocorticoid treatment is associated with clinical and laboratory improvement achieved in patients with acute asthma exacerbations."
06/16/1997 - "These findings demonstrate that lung-specific IL-5 expression can induce pathologic changes characteristic of asthma and may provide useful models to evaluate the efficacy of potential respiratory disease therapies or pharmaceuticals."
10/01/2012 - "Concentration of IL-5, CCL17, CCL22 and CCL26 (ELISA) together with cell expression of T-helper-related genes (real-time PCR array) were measured in bronchoalveolar lavage fluid (BALF) sampled from 11 patients with active CSS, 11 patients with CSS in remission and 9 control subjects with bronchial asthma. "
10/01/2001 - "Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma."
11/20/2009 - "Compared with control group, the study group presented a neutrophil pattern of airway inflammation and an elevated concentration of IL-5, -6, -8 with no significant difference regarding eosinophil count. "
01/01/2001 - "These studies confirm that IL-5 dependent eosinophilic inflammation plays an essential role in the development of certain aspects of airway function after rechallenge of sensitized mice and that lymphocytes and neutrophils are also important in the development of altered airway function. "
02/01/2000 - "As very little is known about the function of IL-5 in the colon, the aim of this study was to assess its role in colonic inflammation. "
02/01/1999 - "These studies indicate the critical involvement of IL-5 and IL-5R in the induction of Eo-B differentiation and eosinophilic airway inflammation in allergic asthmatics, and point to these events as potential targets for long-term therapy of atopic disease."
01/01/1995 - "In the present study, the role of interleukin-5 (IL-5) in virus-induced airway hyperresponsiveness and inflammation was examined in guinea pigs. "
07/01/2004 - "Expression plasmid for IL-5 was most effective in slowing the development of infection among three expression plasmids. "
02/01/1999 - "Production of high levels of IL-5 correlated with blood and tissue eosinophil mobilization during the clearance of a challenge infection."
10/01/2003 - "Impaired clearance of primary but not secondary Brugia infections in IL-5 deficient mice."
03/01/2000 - "The activation of eosinophils was accompanied by changes in IL-5 concentration, but these changes were not associated with differences in protection against infection."
12/01/2011 - "Intermediary levels of mainly IL-5, IFNγ and PBMC stimulation indices were observed for study individuals who changed from being infection positive in 1975 to infection negative in 1996, or vice versa, suggesting a transition in cellular immunoresponsiveness associated with changing infection status. "
05/01/2009 - "There was a significant reduction in lung eosinophilia and IL-5 in high-fat fed mice. "
11/01/2009 - "In vivo, interleukin-5 transgenic mice, which have profound eosinophilia, demonstrated improved clearance of Pseudomonas aeruginosa introduced into the peritoneal cavity. "
10/01/1992 - "Following steroid therapy, pleural fluid disappeared, eosinophilia improved and serum IL-5 concentration became undetectable. "
02/01/2009 - "In the present study, the dependence of PGD(2)-induced eosinophil accumulation in vivo on interleukin-5 (IL-5) blood eosinophilia was investigated. "
03/15/2002 - "However, studies using anti-IL-5 mAbs in human asthmatics have failed to suppress lower airway hyperresponsiveness despite suppression of eosinophilia; therefore, it is critical to examine the role of IL-5 and bone marrow responses in the pathogenesis of allergic airway disease. "
12/01/2003 - "The development of these MAbs will enable the assay of ovine IL-5 in vitro and permit studies into the role of hypersensitivity reactions in sheep by neutralisation of IL-5 in vivo."
06/01/2002 - "Recent studies using experimental models of eosinophil-associated gastrointestinal allergy have revealed differential roles for IL-5 and eotaxin in the modulation of eosinophil accumulation into various regions of the gastrointestinal tract. "
05/01/2014 - "The regulation of IL-5 seems critical for the treatment of eosinophil-mediated allergic reactions. "
01/01/2014 - "Two different Th2 subsets have been defined recently on the basis of IL-5 expression - an IL-5(+)Th2 subset and an IL-5(-)Th2 subset in the setting of allergy. "
01/01/2014 - "Local hypersensitivity reaction in transgenic mice with squamous epithelial IL-5 overexpression provides a novel model of eosinophilic oesophagitis."
|2.||Interleukin-4 (Interleukin 4)
|3.||Immunoglobulin E (IgE)
|4.||Messenger RNA (mRNA)
|6.||Interleukin-10 (Interleukin 10)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||Interferon-gamma (Interferon, gamma)